Ginkgo Bioworks Holdings Inc. (DNA) saw its stock plunge 12.63% in pre-market trading on Wednesday, February 26, 2025, following the release of its fourth quarter and full-year 2024 financial results.
The biotech company reported a wider net loss of $547 million in 2024, compared to $893 million in the previous year. Ginkgo incurred $24.2 million in restructuring charges during 2024, including employee termination costs and impairment of lease assets, as part of its plan to achieve cost reductions and reach profitability by 2026.
The key factor contributing to the stock's pre-market slump was the company's weak revenue guidance for 2025. Ginkgo expects total revenue of $160-$180 million, lower than analysts' expectations, with its Biosecurity segment facing potential headwinds due to government funding availability. The Biosecurity segment reported a 51% year-over-year decline in revenue to $53 million in 2024, impacted by a transition from K-12 testing to a more recurring business model.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。